Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) (344352)

From US Department of Health & Human Services: National Institutes of Health (NIH)

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

Type of Support

Overview

The grant program aims to support the progression of advanced HIV-1 vaccine candidates from pre-clinical studies to clinical testing phases. It focuses on facilitating technology transfer, preclinical immunogenicity, optimization studies, process and product development conforming to Current Good Manufacturing Practice (CGMP) standards, and regulatory filing. The grant encourages collaboration with Pharma/Biotech/Contract Manufacturing Organizations for CGMP manufacture, quality assurance/control, and regulatory submission preparation for clinical trials. Financially, it limits application budgets to $3 million direct costs per year for the first and second years of the award.

Eligibility

Organization's Location
nisi ea
Program Location
do
Organization Type
up to 6M

Submission

Schedule
Step 1: pariatur ut consequat
Application deadline
Dec 19, 2024
Step 2: reprehenderit magna (irure est)

Similar grants